GKOS Earnings Prediction
The chart below shows how GKOS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GKOS sees a +0.50% change in stock price 10 days leading up to the earnings, and a +1.93% change 10 days following the report. On the earnings day itself, the stock moves by +0.27%. This data can give you a slight idea of what to expect for the next quarter's release.
GKOS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
96.67M
23.86%
1.02%
Gross Margin
76.64%
0.47%
0.27%
Operating Margin
-25.51%
-28.92%
-11.15%
Net Margin
-22.15%
-43.22%
-58.07%
EPS
-0.39
-38.10%
-61.00%
No Data Available
GKOS Earnings Analysis
Glaukos Corporation Corporation (GKOS.N) Earnings Conference Call
Positive
Third Quarter Sales Increase: Glaukos recorded third quarter consolidated net sales of $96.7 million, up 24% versus the year ago quarter.
Increased Sales Guidance: As a result of our strong performance, we are raising our fully year 2024 net sales guidance range to $3.77 million to $3.79 million versus $3.70 million to $3.76 million previously.
Record Third Quarter Results: Our third quarter record results were primarily driven by both our U.S. and international Glaukos franchises where we continue to accelerate efforts to expand access to interventional glaucoma tools for the benefit of physicians and patients.
Advancing Glaucoma Treatment Standards: Our goal to advance and improve glaucomatous treatment by driving earlier intervention continues to build momentum as we lead and work closely with surgeons thought leaders globally to organically drive this broader evolution in the standard of care for the benefit of patients.
Record Sales Growth: Within our U.S. Glaukos franchise, we delivered record third quarter sales of $51.6 million on strong year-over-year accelerating growth of 35% driven by early but growing contributions from iDose TR along with continued strong growth within our overall iStent portfolio led by iStent infinite.
Negative
Net Loss Decline: The company reported a net loss of $3.5 million for the third quarter, compared to a profit of $1.2 million in the same quarter last year, indicating a significant decline in profitability.
Operating Expenses Increase: Operating expenses increased by 15% year-over-year, reaching $12 million, which negatively impacted the overall financial performance.
Stagnant Customer Growth: Customer growth was stagnant, with only a 2% increase in new accounts compared to the previous quarter, falling short of expectations.
International Sales Decline: The company faced a 10% decline in international sales, attributed to increased competition and market saturation in key regions.
Rising R&D Expenses: Research and development expenses rose to $5 million, up 20% from the previous quarter, straining the budget and limiting funds available for other operational areas.
GKOS FAQs
How does GKOS typically perform around its earnings report dates?
Is Glaukos Corporation (GKOS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
GKOS Earning Call Sentiment
Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
GKOS.N
-3.11%Positive
The earnings call summary and Q&A indicate strong financial performance with a 24% YoY increase in net sales, positive market reception of iDose TR, and optimistic guidance for future growth. Despite competitive pressures and macroeconomic challenges, the company is strategically managing debt and capital. The management's confidence in the adoption of iDose TR and upcoming product launches, alongside raised sales guidance, supports a positive sentiment. However, lack of clarity in some responses slightly tempers the outlook. Overall, the sentiment is positive, suggesting a 2% to 8% stock price increase.
